Simcere Pharmaceutical Group Limited (2096.HK)

Name: Simcere Pharmaceutical Group Limited Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2026-04-09

Latest Quarter

2026-04-09

Revenue

$3.6B

Net Income

$604M

Operating Margin

19.1%

Free Cash Flow

$629M

Debt / Assets

38.6%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Simcere Pharmaceutical Group Limited (2096.HK).
Income Statement (Quarterly)	2026-04-09	2025-06-30	2025-03-31	2024-12-31
Revenue	3,584,912,000	3,584,912,000	1,792,456,000	1,760,843,500
Cost of Revenue	691,062,000	691,062,000	345,531,000	329,520,000
Gross Profit	2,893,850,000	2,893,850,000	1,446,925,000	1,431,323,500
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	1,615,564,000	1,615,564,000	807,782,000	822,832,000
Operating Expenses	2,209,204,000	2,209,204,000	1,104,602,000	1,253,380,000
Operating Income	684,646,000	684,646,000	342,323,000	177,943,500
Interest Expense	0	21,988,000	0	0
Income Before Tax	662,485,000	662,485,000	331,242,500	162,592,500
Income Tax Expense	58,878,000	58,878,000	29,439,000	24,310,000
Net Income	603,607,000	603,607,000	301,803,500	138,282,500
Per Share
EPS	0.24	0.24	0.12	0.06
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Simcere Pharmaceutical Group Limited (2096.HK).
Income Statement (Annual)	2024-12-31	2023-12-31	2023-06-30	2022-12-31	2021-12-31
Revenue	6,635,211,000	6,607,805,000	0	6,319,096,000	4,999,718,000
Cost of Revenue	1,310,632,000	1,623,652,000	0	1,322,246,000	1,079,983,000
Gross Profit	5,324,579,000	4,984,153,000	0	4,996,850,000	3,919,735,000
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	3,030,264,000	2,844,215,000	0	2,846,572,000	2,419,190,000
Operating Expenses	4,476,532,000	4,272,351,000	0	4,420,319,000	3,703,751,000
Operating Income	848,047,000	711,802,000	0	862,505,000	1,448,544,000
Interest Expense	69,557,000	34,568,000	0	34,408,000	70,848,000
Income Before Tax	819,878,000	740,038,000	0	888,154,000	1,401,797,000
Income Tax Expense	86,713,000	26,088,000	0	-40,478,000	-97,124,000
Net Income	733,165,000	714,761,000	0	932,768,000	1,507,096,000
Per Share
EPS	0.29	0.27	0.00	0.40	0.58
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Simcere Pharmaceutical Group Limited (2096.HK).
Balance Sheet (Quarterly)	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Assets
Cash and Cash Equivalents	1,943,069,000	2,007,162,000	1,657,600,000	973,139,000
Short Term Investments	0	11,137,000	964,226,000	1,210,078,000
Net Receivables	2,710,068,000	2,644,645,000	2,337,443,000	0
Inventory	593,649,000	770,139,000	302,373,000	235,157,000
Total Current Assets	5,465,743,000	5,638,944,000	5,453,784,000	4,979,549,000
Property Plant Equipment	2,269,544,000	2,170,339,000	2,171,910,000	1,961,644,000
Goodwill and Intangibles	1,167,912,000	858,260,000	552,684,000	232,479,000
Total Assets	11,509,927,000	10,853,667,000	10,781,113,000	10,161,143,000
Liabilities
Account Payables	275,725,000	317,218,000	334,444,000	323,951,000
Short Term Debt	1,118,698,000	1,094,981,000	1,350,823,000	1,561,643,000
Total Current Liabilities	2,726,979,000	2,685,900,000	2,963,728,000	3,063,763,000
Long Term Debt	90,671,000	334,243,000	155,921,000	74,239,000
Total Liabilities	4,441,812,000	3,630,931,000	3,638,290,000	3,698,386,000
Shareholders Equity
Retained Earnings	3,481,021,000	3,837,325,000	3,061,248,000	0
Total Shareholders Equity	7,068,115,000	7,222,736,000	7,126,761,000	6,436,997,000

Balance sheet annual history for Simcere Pharmaceutical Group Limited (2096.HK).
Balance Sheet (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Assets
Cash and Cash Equivalents	1,943,069,000	2,007,162,000	1,657,600,000	973,139,000	3,270,241,000
Short Term Investments	0	11,137,000	964,226,000	1,210,078,000	3,634,000
Net Receivables	2,710,068,000	2,644,645,000	2,337,443,000	0	0
Inventory	593,649,000	770,139,000	302,373,000	235,157,000	262,673,000
Total Current Assets	5,465,743,000	5,638,944,000	5,453,784,000	4,979,549,000	6,466,832,000
Property Plant Equipment	2,269,544,000	2,170,339,000	2,171,910,000	1,961,644,000	2,191,413,000
Goodwill and Intangibles	1,167,912,000	858,260,000	552,684,000	232,479,000	249,896,000
Total Assets	11,509,927,000	10,853,667,000	10,781,113,000	10,161,143,000	10,943,410,000
Liabilities
Account Payables	275,725,000	317,218,000	334,444,000	323,951,000	242,077,000
Short Term Debt	1,118,698,000	1,094,981,000	1,350,823,000	1,561,643,000	1,792,940,000
Total Current Liabilities	2,726,979,000	2,685,900,000	2,963,728,000	3,063,763,000	3,497,158,000
Long Term Debt	90,671,000	334,243,000	155,921,000	74,239,000	1,275,550,000
Total Liabilities	4,441,812,000	3,630,931,000	3,638,290,000	3,698,386,000	5,607,686,000
Shareholders Equity
Retained Earnings	3,481,021,000	3,837,325,000	3,061,248,000	0	0
Total Shareholders Equity	7,068,115,000	7,222,736,000	7,126,761,000	6,436,997,000	5,335,724,000

Cash flow quarterly history for Simcere Pharmaceutical Group Limited (2096.HK).
Cash Flow Statement (Quarterly)	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Operating Activities
Net Income	819,878,000	740,038,000	888,154,000	1,507,096,000
Depreciation & Amortization	337,647,000	309,594,000	282,928,000	251,807,000
Stock Based Compensation	97,810,000	12,119,000	138,290,000	62,392,000
Change in Working Capital	-81,557,000	-946,751,000	79,074,000	-769,246,000
Operating Cash Flow	1,391,116,000	151,048,000	1,354,712,000	-201,970,000
Investing Activities
Capital Expenditure	-762,572,000	-979,855,000	-678,005,000	-209,488,000
Investments	-356,972,000	-483,182,000	-678,005,000	-209,488,000
Investing Cash Flow	-1,050,092,000	1,087,807,000	68,306,000	-435,503,000
Financing Activities
Debt Repayment	-161,712,000	-151,071,000	-1,184,161,000	-2,463,778,000
Common Stock Issued/Repurchased	-687,985,000	-289,073,000	0	0
Dividends Paid	-401,484,000	-419,218,000	-391,296,000	-391,296,000
Financing Cash Flow	-407,403,000	-894,834,000	-753,681,000	-1,624,531,000
Summary
Free Cash Flow	628,544,000	-828,807,000	676,707,000	-411,458,000
Net Change in Cash	-64,093,000	348,850,000	684,461,000	-2,297,102,000

Cash flow annual history for Simcere Pharmaceutical Group Limited (2096.HK).
Cash Flow Statement (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Operating Activities
Net Income	819,878,000	740,038,000	888,154,000	1,507,096,000	669,534,000
Depreciation & Amortization	337,647,000	309,594,000	282,928,000	251,807,000	222,329,000
Stock Based Compensation	97,810,000	12,119,000	138,290,000	62,392,000	32,797,000
Change in Working Capital	-81,557,000	-946,751,000	79,074,000	-769,246,000	-462,178,000
Operating Cash Flow	1,391,116,000	151,048,000	1,354,712,000	-201,970,000	96,731,000
Investing Activities
Capital Expenditure	-762,572,000	-979,855,000	-678,005,000	-209,488,000	-352,841,000
Investments	-356,972,000	-483,182,000	-678,005,000	-209,488,000	-352,841,000
Investing Cash Flow	-1,050,092,000	1,087,807,000	68,306,000	-435,503,000	529,083,000
Financing Activities
Debt Repayment	-161,712,000	-151,071,000	-1,184,161,000	-2,463,778,000	-1,824,871,000
Common Stock Issued/Repurchased	-687,985,000	-289,073,000	0	0	3,007,932,000
Dividends Paid	-401,484,000	-419,218,000	-391,296,000	-391,296,000	0
Financing Cash Flow	-407,403,000	-894,834,000	-753,681,000	-1,624,531,000	2,353,622,000
Summary
Free Cash Flow	628,544,000	-828,807,000	676,707,000	-411,458,000	-256,110,000
Net Change in Cash	-64,093,000	348,850,000	684,461,000	-2,297,102,000	2,915,437,000